There is constant remodeling in a cirrhotic liver resulting in cirrhosis being spatially heterogeneous. The Laennec system, and, more recently the Beijing classification, have been used to sub-classify various degrees of cirrhosis. It is unknown how these two schemes compare with each other, how they are impacted by geographic variation, and how they correlate with clinical outcomes. Five needle biopsies were obtained from 20 explanted cirrhotic HCV livers at the time of transplantation. Collagen proportionate area (CPA) was measured by computerized quantitative morphometry. The Laennec system (4A-4C indicating increasing degrees of cirrhosis) and Beijing classification (P—progressive, R—regressive, I—indeterminate) were assessed and then correlated with CPA. Geographical variation using CPAs was calculated by the coefficient of variation (CoV). CPA of Laennec 4C cirrhosis was higher than 4A (p = 0.00008) or 4B (p = 0.0002). The CPA of the P pattern was greater than the R (p = 0.002) or I patterns (p = 0.037). The mean CoV of the five CPAs was 47.3 ± 4.5%, suggesting a significant degree of geographic variation. There was 100% overlap between the Beijing R pattern and Laennec 4A, and 80% overlap between the P pattern and Laennec 4C. Patients’ platelet counts of P pattern were lower than R pattern (p = 0.008) or I pattern (p = 0.024), while Laennec 4C was lower than 4A (p = 0.036) and 4B patients (p = 0.7). There was no correlation between CPA, Laennec stage, or Beijing classification and MELD score, liver weights, total bilirubin, or albumin levels. The Laennec system and the Beijing classification are highly correlated with CPA in cirrhosis. This study confirms that there is a significant degree of geographic variation in terms of fibrosis content and cirrhosis morphology throughout the liver.
This is a preview of subscription content, access via your institution
Subscribe to Journal
Get full journal access for 1 year
We are sorry, but there is no personal subscription option available for your country.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Trivedi, H. D., Patwardhan, V. R. & Malik, R. Chronic hepatitis C infection — noninvasive assessment of liver fibrosis in the era of direct acting antivirals. Dig. Liver Dis. 51, 183–189 (2019).
Gonzalez, H. C., Jafri, S. M. & Gordon, S. C. Role of liver biopsy in the era of direct-acting antivirals. Curr. Gastroenterol. Rep. 15, 307–314 (2017).
Kanwal, F. & Singal, A. G. Surveillance for hepatocellular carcinoma: current best practice and future direction. Gastroenterology. 157, 54–64 (2019).
Singal, A. G., Lim, J. K. & Kanwal, F. AGA clinical practice update on interaction between oral direct-acting antivirals for chronic hepatitis C infection and hepatocellular carcinoma: expert review. Gastroenterology. 156, 2149–2157 (2019).
D’Amico, G. et al. Clinical states of cirrhosis and competing risks. J. Hepatol. 68, 563–576 (2018).
Jacobson, I. M., Lim, J. K. & Fried, M. W. American gastroenterological association institute clinical practice update—expert review: care of patients who have achieved a sustained virologic response after antiviral therapy for chronic hepatitis C infection. Gastroenterology. 152, 1578–1587 (2017).
Pinzani, M. Liver fibrosis in the post-HCV era. Semin. Liver. Dis. 35, 157–165 (2015).
Patel, K. et al. Correlation of FIBROSpect II with hist ologic and morphometric evaluation of liver fibrosis in chronic hepatitis C. Clin. Gastroenterol. Hepatol. 6, 242–247 (2008).
Rinella, M. E. & Sanyal, A. J. Management of NAFLD: a stage-based approach. Nat. Rev. Gastroenterol. Hepatol. 13, 196–205 (2016).
Schuppan, D., Surabattula, R. & Wang, X. Y. Determinants of fibrosis progression and regression in NASH. J. Hepatol. 68, 238–250 (2018).
Bruno, S. et al. Sustained virologic response prevents the development of esophageal varices in compensated, child-pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology. 51, 2069–2076 (2010).
Van Der Meer, A. J. et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA - J. Am. Med. Assoc. 308, 2584–2593 (2012).
Morgan, R. L. et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann. Intern. Med. 158, 329–337 (2013).
Mauro, E. et al. Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C. Hepatology. 67, 1683–1694 (2018).
Hytiroglou, P. & Theise, N. D. Regression of human cirrhosis: an update, 18 years after the pioneering article by Wanless et al. Virchows. Arch. 473, 15–22 (2018).
Tacke, F. & Trautwein, C. Mechanisms of liver fibrosis resolution. J. Hepatol. 63, 1038–1039 (2015).
Trautwein, C., Friedman, S. L., Schuppan, D. & Pinzani, M. Hepatic fibrosis: concept to treatment. J. Hepatol. 62, S15–S24 (2015).
Hamdane, N. et al. HCV-induced epigenetic changes associated with liver cancer risk persist after sustained virologic response. Gastroenterology. 156, 2313–2329 (2019).
Ramachandran, P., Iredale, J. P. & Fallowfield, J. A. Resolution of liver fibrosis: basic mechanisms and clinical relevance. Semin. Liver. Dis. 35, 119–131 (2015).
Kutami, R. et al. The Laennec grading system for assessment of hepatic fibrosis: validation by correlation with wedged hepatic vein pressure and clinical features. Hepatology. 32, 407A (2000).
Sun, Y. et al. New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment. Hepatology. 65, 1438–1450 (2017).
D’Ambrosio, R. et al. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology. 56, 532–543 (2012).
Wang, B. et al. Advanced septa size quantitation determines the evaluation of histological fibrosis outcome in chronic hepatitis B patients. Mod. Pathol. 31, 1567–1577 (2018).
Harrison, S. A. et al. Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis. Gastroenterology. 155, 1140–1153 (2018).
Ooi, G. J. et al. Evaluation of the histological variability of core and wedge biopsies in nonalcoholic fatty liver disease in bariatric surgical patients. Surg. Endosc. 35, 1210–1218 (2020).
This study was funded in part with a grant from Merck Pharmaceutical Company. We thank Brandy Haydel for her invaluable assistance in obtaining the pathology specimens. The study was sponsored in part by Merck Pharmaceuticals.
The authors declare no competing interests.
Ethics approval/consent to participate
Each patient gave consent to participate in the study. The study was approved by the Institutional Review Board.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Zhang, X., Schiano, T.D., Doyle, E. et al. A comparative study of cirrhosis sub-staging using the Laennec system, Beijing classification, and morphometry. Mod Pathol 34, 2175–2182 (2021). https://doi.org/10.1038/s41379-021-00881-z